XBiotech Inc.
NASDAQ:XBITBiotechnology
Healthcare
$1.68 -0.84%
-$0.02 today
- Market cap
- $51.22M
- Beta
- 0.84
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.32
52W Low $2.09High $3.61
Volume 0.05M
Average 0.03M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$55.69M
FY 2025 · Annual
Net Income
-$45.54M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.39M | 4.01M | 0 | 0 | 0 |
| Cost of Revenue | 5.82M | 651K | 0 | 0 | 1.69M |
| Gross Profit | 12.57M | 3.36M | 0 | 0 | (1.69M) |
| Gross Margin | 68.4% | 83.8% | — | — | — |
| Research & Development | 28.27M | 31.54M | 32.85M | 37.76M | 47.39M |
| Selling, General & Admin | 9.39M | 6.31M | 4.66M | 4.71M | 8.3M |
| Operating Expenses | 37.66M | 37.85M | 37.51M | 42.47M | 54M |
| Depreciation & Amortization | 2.65M | 2.61M | 1.74M | 1.75M | 1.69M |
| EBITDA | (22.81M) | (30.97M) | (22.57M) | (36.01M) | (43.53M) |
| EBITDA Margin | -124.0% | -772.4% | — | — | — |
| Operating Income | (25.08M) | (34.49M) | (37.51M) | (42.47M) | (55.69M) |
| Operating Margin | -136.4% | -860.1% | — | — | — |
| Interest Income | 467K | 3.82M | 10.42M | 9.81M | 5.68M |
| Interest Expense | 0 | 0 | 0 | 807K | 88K |
| Other Income / Expenses | (376K) | 902K | 13.2M | 3.91M | 10.38M |
| Income Before Tax | (25.46M) | (33.59M) | (24.31M) | (38.56M) | (45.31M) |
| Pre-Tax Margin | -138.4% | -837.6% | — | — | — |
| Income Tax Expense | (8.04M) | (688K) | 244K | (32K) | 235K |
| Net Income | (17.41M) | (32.9M) | (24.56M) | (38.53M) | (45.54M) |
| Net Margin | -94.7% | -820.4% | — | — | — |
| EPS (Basic) | (0.58) | (1.08) | (0.81) | (1.26) | (1.49) |
| EPS (Diluted) | (0.58) | (1.08) | (0.81) | (1.26) | (1.49) |
| 30.04M | 30.44M | 30.32M | 30.46M | 30.49M | |
| 30.04M | 30.44M | 30.44M | 30.46M | 30.49M |
XBIT Earnings Waterfall · TTM
NASDAQ:XBIT · Revenue to Net Income
Key Ratios
EPS$-1.32
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$40.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.32, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 28, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 28, 2026 |
How much revenue does XBIT generate?
XBiotech Inc. (XBIT) reported $0.00 of revenue in fiscal 2025.
Is XBIT profitable?
XBiotech Inc. (XBIT) reported -$45.54M of net income.
Continue the stock analysis
Jump to another research area for this company.